Compare Stocks → (Free Workshop) Advanced “bug-out bag” hacks! (From Warrior Life) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:TPST Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTPSTTempest Therapeutics$2.90-4.3%$3.37$0.17▼$9.77$64.44M-1.78754,784 shs569,200 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTPSTTempest Therapeutics0.00%-6.75%-8.81%-25.06%+114.81%(Free Workshop) Advanced “bug-out bag” hacks! (Ad)“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” Most citizens don’t… but according to my friend (and best-selling survival author), Jeff, even the hardcore “preppers” who cherish their bug-out bags are doing it all wrong!All the details are right here…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTPSTTempest Therapeutics1.4106 of 5 stars3.53.00.00.03.30.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTPSTTempest Therapeutics3.00Buy$25.00762.07% UpsideCurrent Analyst RatingsLatest TPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2024TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.003/20/2024TPSTTempest TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/20/2024TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00(Data available from 6/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTPSTTempest TherapeuticsN/AN/AN/AN/A$1.39 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTPSTTempest Therapeutics-$29.49M-$1.72N/AN/AN/AN/A-232.39%-78.98%8/8/2024 (Estimated)Latest TPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024TPSTTempest Therapeutics-$0.44-$0.36+$0.08-$0.36N/AN/A3/19/2024Q4 2023TPSTTempest Therapeutics-$0.38-$0.34+$0.04-$0.34N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTPSTTempest TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTPSTTempest Therapeutics0.203.133.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipTPSTTempest Therapeutics3.27%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableTPSTTempest Therapeutics1722.22 million21.49 millionOptionableTPST HeadlinesRecent News About These CompaniesJune 7, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 31, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)May 21, 2024 | finance.yahoo.comTempest to Participate in Upcoming Investor ConferencesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical AdvancementsMay 10, 2024 | finanznachrichten.deTempest Therapeutics: Tempest Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | markets.businessinsider.comTPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024May 9, 2024 | globenewswire.comTempest Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 26, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 9, 2024 | markets.businessinsider.comBuy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug DevelopmentsApril 9, 2024 | finance.yahoo.comTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingApril 9, 2024 | globenewswire.comTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingApril 6, 2024 | uk.investing.comTempest Therapeutics moves TPST-1120 into phase 3 trialApril 4, 2024 | finance.yahoo.comTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsApril 4, 2024 | globenewswire.comTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsMarch 21, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)March 20, 2024 | finanznachrichten.deTempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | investorplace.comTPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comTempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | globenewswire.comTempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 14, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsTempest TherapeuticsNASDAQ:TPSTTempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.